ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Canon invests in T2 Biosystems

by Marc S. Reisch
October 3, 2016 | APPEARED IN VOLUME 94, ISSUE 39

Canon USA has purchased a nearly 20% stake in T2 Biosystems, a maker of time-domain nuclear magnetic resonance diagnostics, for $40 million. T2 has worked with the molecular diagnostics arm of Canon since 2015 to develop a test panel for Lyme disease. T2 expects to use the funds to grow its business and launch a sepsis detection panel in 2017. The firm’s technology was developed by scientists at Massachusetts General Hospital and MIT.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment